Orca Bio has disclosed $250 million in funding, flooding its balance sheet with cash to buoy preparations for the ...

The use of base editing to generate universal off-the-shelf CAR T cells induced durable remissions -- up to 36 months in one ...

Some parts of our bodies bounce back from injury in fairly short order. The outer protective layer of the eye—called the ...

Higher levels of CD4-positive naïve T cells in patients receiving CAR T-cell therapy for multiple myeloma are associated with ...

Data presented at ASH 2025 suggest earlier-line use of cilta-cel leads to better outcomes in multiple myeloma because patients have fitter immune systems and less exhausted T cells, improving CAR T ...

Cell and gene therapies use the body's building blocks - cells and genetic material - to boost the immune system or correct ...

Cell-based immunotherapies have transformed cancer treatment, yet their widespread use remains constrained by safety risks, ...

For the first time, researchers at the University of British Columbia have demonstrated how to reliably produce an important ...

Glioblastoma remains one of the most challenging solid tumors to treat due to its highly immunosuppressive tumor microenvironment.

In patients with relapsed or refractory systemic lupus erythematosus, allogeneic CAR-NK cell therapy may offer a safe ...

Formerly Somite AI, the rebranded company aims to broaden the regenerative medicine landscape by building AI models that ...

Immune cells are most commonly engineered to kill cancers, but now, scientists have shown the technique makes the gut lining ...